Lipid-lowering therapy: who can benefit

Lipid-lowering therapy: who can benefit?

Cardiovascular disease (CVD) is the leading cause of death in the US. Despite the decline in CVD-associated mortality rates in recent years, coronary heart disease (CHD) still causes one in every six deaths in this country. Because most CHD risk factors are modifiable (eg, smoking, hypertension, obesity, onset of type 2 diabetes, and dyslipidemia), cardiovascular risk can be reduced by timely a...

Statins: Newer Roles Including Lipid Lowering Therapy

Statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of HMG-Co A reductase. Apart from the well-known LDL and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. Better understanding of various pleotropic effects of statins has prompted a new s...

Superior Benefit of Aggressive Lipid-Lowering Therapy for High- Risk Patients Using Statins: the SUBARU Study

Aim: There have been few comparisons between rosuvastatin and other statins in Japanese patients. This open-label, randomized, parallel-group comparative study was performed to compare the efficacy and safety of rosuvastatin (5 mg) and atorvastatin (10 mg) once daily in Japanese patients with hypercholesterolemia. Methods: Patients with hypercholesterolemia who had received atorvastatin (10 mg/...

Shifting views on lipid lowering therapy.

A Role for Lipid Lowering Therapy?

Over the past 3 decades, childhood obesity has increased dramatically and has been deemed an epidemic by the Centers for Disease Control and Prevention.1 The 2002 National Health and Nutrition Examination Survey reported that the prevalence of overweight and obese children aged 6 to 19 years was 31%, a 45% increase from the previous survey.2 Obesity has been linked to comorbid conditions in chi...